Gerresheimer upgrades revenue guidance after strong burst of growth

Dusseldorf (ots) -

- Cross-reference: Press release including Group Key Figures is
available at http://www.presseportal.de/dokumente -

- Group revenues climbed 9.9 percent in the third quarter of 2011
and 13.4 percent at constant exchange rates
- Net income grew by 36 percent to EUR 19.2m
- Revenue guidance was raised to 7 to 8 percent growth at
constant exchange rates (previously 6 to 7 percent)

Gerresheimer AG, one of the leading worldwide suppliers to the
pharma and healthcare industry, reports strong growth in the third
quarter of the 2011 financial year. "With a strong burst of growth in
the third quarter we gained ground and further developed our strong
market position. Our medical plastics systems business did extremely
well. As a result, we have raised our revenue guidance for the
current year to 7 to 8 percent growth at constant exchange rates,"
said Uwe Röhrhoff, CEO of Gerresheimer AG.

Gerresheimer reports revenue growth of 9.9 percent to EUR 285.1m
for the third quarter of the 2011 financial year (June 1, 2011 to
August 31, 2011). At constant exchange rates, the growth rate
compared to last year is 13.4 percent. In the Plastic Systems
Division, the segments of insulin pen systems, inhalers and
diagnostics experienced particularly dynamic growth. Vedat, the South
American company that Gerresheimer acquired in March 2011, also
contributed to this positive revenue development.

Gerresheimer reports adjusted EBITDA of EUR 57.1m (prior year: EUR
53.3m) in the third quarter of 2011. The adjusted EBITDA margin of
20.0 percent was slightly lower than the margin in the same quarter
last year. Net income increased by EUR 5.1m to EUR 19.2m. Adjusted
earnings per share rose by 35 percent to EUR 0.70. In the third
quarter of 2010 adjusted EPS stood at EUR 0.52.

"The pharma market will continue to grow. However, the main growth
drivers will change. In future, main growth drivers will be the
emerging markets and the generic drugs, whilst complex drug delivery
systems are gaining significance in Western industrialized nations.
We are already in an excellent position to satisfy these changing
requirements with our comprehensive product portfolio and our strong
presence in South America and China and we are going to strengthen
our position further," commented Röhrhoff.

Outlook

Gerresheimer has raised its revenue guidance for 2011 from 6 to 7
percent to 7 to 8 percent growth at constant exchange rates. Guidance
for the adjusted EBITDA margin remains unchanged at approximately
20.0 percent. Due to the strong project pipeline in the Plastic
Systems Division and the associated prospect of lining up new
business the capital expenditure in the financial year 2011 has been
raised from EUR 80m to around EUR 85m.

press contact:
Gerresheimer AG
Benrather Strasse 18 - 20
40213 Düsseldorf
Germany

Jens Kürten
Director Corporate Communication & Marketing
Telephone +49 211 6181-250
Fax +49 211 6181-241
E-Mail j.kuerten@gerresheimer.com
Internet www.gerresheimer.com